Proteasome inhibitors: all 957 studies that test it

Page 3 of 10. Open to participants first (61), then studies with results posted, then the rest; newest registration first within each.

• Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple MyelomaCompletedNCT01849783Phase 2Results posted
• Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01842308Phase 1/2Results posted
• Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12DCompletedNCT01833143Phase 2Results posted
• Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT01832727Phase 1/2Results posted
• Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal ImpairmentCompletedNCT01830816Phase 1Results posted
• Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Phase 3Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01816971Phase 2Results posted
• A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531CompletedNCT01813227Phase 2Results posted
• A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple MyelomaCompletedNCT01801436Phase 3Results posted
• Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)CompletedNCT01782963Phase 2Results posted
• Carfilzomib in Refractory Renal Cell Carcinoma (RCC)CompletedNCT01775930Phase 2Results posted
• Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose CarfilzomibCompletedNCT01775553Phase 2Results posted
• Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart TransplantationTerminatedNCT01769443Phase 2Results posted
• Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT01769209Phase 2Results posted
• Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell TransplantCompletedNCT01754389Phase 2Results posted
• Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell LymphomaTerminatedNCT01738594Phase 1Results posted
• Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous LeukemiaCompletedNCT01736943Phase 2Results posted
• Velcade + Cyclophosphamide in Newly Diagnosed Multiple MyelomaTerminatedNCT01729338Phase 2Results posted
• Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma PatientsTerminatedNCT01720043Phase 2Results posted
• Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01718743Phase 2Results posted
• Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell TransplantCompletedNCT01706666Phase 2Results posted
• Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing RegimensTerminatedNCT01695330Phase 2Results posted
• Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell TransplantationCompletedNCT01690143Phase 1/2Results posted
• A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple MyelomaCompletedNCT01677858Phase 1/2Results posted
• A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple MyelomaTerminatedNCT01672736Phase 1/2Results posted
• Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) AmyloidosisTerminatedNCT01659658Phase 3Results posted
• Carfilzomib and Stem Cell Transplant for Plasma Cell MyelomaTerminatedNCT01658904Phase 1/2Results posted
• Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell TransplantationTerminatedNCT01653418Phase 2Results posted
• Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01645930Phase 1Results posted
• Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01605032Phase 2Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple MyelomaCompletedNCT01572480Phase 2Results posted
• Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma PatientsCompletedNCT01568866Phase 3Results posted
• A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01564537Phase 3Results posted
• Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple MyelomaCompletedNCT01559935Phase 2Results posted
• Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior TreatmentTerminatedNCT01548573Phase 2Results posted
• Velcade (Bortezomib) Consolidation After TransplantCompletedNCT01539083Phase 3Results posted
• Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom MacroglobulinemiaTerminatedNCT01536067Phase 2Results posted
• Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive GenotypeCompletedNCT01534260Phase 1/2Results posted
• High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell TransplantTerminatedNCT01534143Phase 2Results posted
• Panitumumab and Bortezomib for Patients With Advanced Colorectal CancerTerminatedNCT01504477Phase 1/2Results posted
• Zevalin and Velcade in Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT01497275Phase 2Results posted
• Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01496118Phase 1/2Results posted
• Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's MacroglobulinemiaCompletedNCT01470196Phase 2Results posted
• Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in RemissionTerminatedNCT01465386Phase 2Results posted
• Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant MelanomaCompletedNCT01462773Phase 1Results posted
• Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or LymphomaCompletedNCT01454076Phase 1Results posted
• Allogeneic Hematopoietic Stem Cell Transplantation for Multiple MyelomaCompletedNCT01453101Phase 2Results posted
• Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or OlderTerminatedNCT01453088Phase 2Results posted
• Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple MyelomaTerminatedNCT01438177Phase 2Results posted
• Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to BortezomibCompletedNCT01415882Phase 2Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma PatientsCompletedNCT01402284Phase 2Results posted
• Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell LymphomaTerminatedNCT01397591Phase 2Results posted
• Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple MyelomaCompletedNCT01383928Phase 1/2Results posted
• Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01371981Phase 3Results posted
• Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01351623Phase 2Results posted
• Treatment of Sickle Cell Anemia With Stem Cell TransplantTerminatedNCT01350232Not applicableResults posted
• Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney TransplantationTerminatedNCT01349595Phase 2Results posted
• Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT01348919Phase 1/2Results posted
• Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple MyelomaCompletedNCT01335685Phase 1/2Results posted
• Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related DonorsCompletedNCT01323920Phase 2Results posted
• Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain AmyloidosisCompletedNCT01318902Phase 1Results posted
• Bortezomib and Bendamustine to Treat Relapsed/Refractory MyelomaTerminatedNCT01315873Phase 2Results posted
• UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple MyelomaCompletedNCT01313897Phase 2Results posted
• Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)TerminatedNCT01312818Phase 2Results posted
• A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT01302392Phase 3Results posted
• Velcade Consolidation Bone StudyCompletedNCT01286077Phase 2Results posted
• Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01281917Phase 2Results posted
• Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell TransplantationCompletedNCT01267812Phase 2Results posted
• Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01246063Phase 1/2Results posted
• Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCTCompletedNCT01242267Phase 1/2Results posted
• Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple MyelomaCompletedNCT01241708Phase 3Results posted
• A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01217957Phase 1/2Results posted
• Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65Active, not recruitingNCT01208662Phase 3Results posted
• Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin LymphomaTerminatedNCT01186458Phase 2Results posted
• Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple MyelomaTerminatedNCT01177683Phase 1/2Results posted
• A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHDTerminatedNCT01163786Phase 2Results posted
• Trial of Three Stem Cell Mobilization Regimens for Multiple MyelomaCompletedNCT01146834Phase 3Results posted
• Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After RituximabTerminatedNCT01119794Phase 2Results posted
• Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)CompletedNCT01109004Phase 3Results posted
• Pilot Study of Velcade® in IgA NephropathyCompletedNCT01103778Phase 4Results posted
• Velcade and Sorafenib in Unresected or Metastatic Renal Cell CarcinomaTerminatedNCT01100242Phase 2Results posted
• Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple MyelomaCompletedNCT01090921Phase 2Results posted
• Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) AmyloidosisCompletedNCT01083316Phase 2Results posted
• Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple MyelomaCompletedNCT01080391Phase 3Results posted
• Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell TransplantTerminatedNCT01078441Phase 2Results posted
• Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain AmyloidosisCompletedNCT01072773Phase 2Results posted
• Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT01062230Phase 2Results posted
• Bortezomib Plus Rituximab for EBV+ PTLDCompletedNCT01058239Phase 2Results posted
• Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple MyelomaCompletedNCT01057225Phase 1/2Results posted
• Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose ChemotherapyCompletedNCT01056276Phase 2Results posted
• Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaCompletedNCT01040871Phase 2Results posted
• Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade LymphomaCompletedNCT01029730Phase 2Results posted
• Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple MyelomaCompletedNCT01029054Phase 1/2Results posted
• IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma PatientsCompletedNCT01009840Phase 2Results posted
• EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia LymphomaCompletedNCT01000285Phase 1/2Results posted
• Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT00998010Phase 2Results posted
• Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaCompletedNCT00992446Phase 2Results posted
• Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & TemozolomideCompletedNCT00990652Phase 2Results posted
• A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)CompletedNCT00985959Phase 1Results posted
• Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple MyelomaTerminatedNCT00985907Phase 1/2Results posted

← Proteasome inhibitors overview